CIDRAP newsletters options
A secondary analysis of an audit-and-feedback intervention targeting antibiotic prescribing for older patients finds reduced prescribing across all age-groups.
The drug fills a treatment gap for the youngest babies, who are too young to be vaccinated.
The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.
The shift reflects the current public health situation, marked by declines in human cases as well as animal detections.
Much less improvement was seen among participants who were Black or lived in rural or disadvantaged areas.
The lawsuit contends that coordinated actions were designed to mislead, confuse, and gradually desensitize the public to anti-vaccine and anti-science rhetoric.
The risk of poor outcomes was especially pronounced during periods of widespread community viral transmission.
Doxycycline post-exposure prophylaxis isn't formally available in the Netherlands, but 23% of respondents to an online survey said they've used it.
Effectiveness against both herpes zoster and postherpetic neuralgia remained stable for at least 4 years after vaccination.
So far, there are no known links between the 2 new cases.
Women and young adults aged 15 to 49 experienced a greater burden of mental illness.
Results point to a need to increase HPV vaccine uptake and screening, the authors say.
More local health departments are losing staff, raising concerns about a shrinking public health safety net.
The latest case marks Cambodia's ninth since early June.
NACCHO selects 5 local health departments as mentors and 11 as mentees for the 2025 Wastewater Monitoring Mentorship Program.
Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake in affected populations.
The April RSV, meningococcal, and chikungunya vaccine recommendations from the previous ACIP panel are now official policy.
With brisk activity in Canada, Mexico, and the US, cases in the Americas region are up 29-fold compared to a year ago.
Compared with flu vaccine recipients, those given the RSV and/or shingles vaccine had 18% to 37% lower odds of receiving a dementia diagnosis in the next 18 months.
Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic year 1, dropping 19% and 14%, respectively, the next year.
